Topic: inflammatory bowel disease
Topline data show that Arena's ulcerative colitis candidate, etrasimod, beat out placebo in phase 2.
If successful in further trials, OPRX-106 could mount a challenge in the market for injectable and infused TNF drugs.
The funding will propel Finch's lead asset through phase 2 and advance its earlier-stage pipeline.
An oral alternative to injectable anti-TNF drugs—a mainstay of inflammatory disease therapy for decades—has shown encouraging activity in a phase 2 trial.
Scientists at Tufts University have created an “organ on a chip” that could be used to study inflammatory bowel disease and other gut disorders.
Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.
The microbiome pioneer thinks the data support the rapid advance of SER-287 deeper into the clinic, although question marks about the results remain.
After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.
The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.
A "blunted" version of CRISPR can be used to identify gene regulators in the genome and help unravel autoimmune disease.